Abdulrahim Refdan Hakami
Impact in
-
- Nigella sativa pharmacological applications
Papers in
-
- COVID-19 Clinical Research Studies 2
- SARS-CoV-2 and COVID-19 Research 2
-
- Computational Drug Discovery Methods 5
- Co-authors
- Ali G. Alkhathami (6 shared papers)Khaled S. Allemailem (3 shared papers)Mohammad Y. Alshahrani (5 shared papers)Irfan S. Ahmad (5 shared papers)Mahmoud Moustafa (2 shared papers)Mahmoud A. A. Ibrahim (2 shared papers)Mohamed A. M. Atia (2 shared papers)Alaa H. M. Abdelrahman (2 shared papers)
- Journals
- Molecules (2 papers)Marine Drugs (1 paper)Journal of Oncology (1 paper)Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (1 paper)Future Medicinal Chemistry (1 paper)
- Partner nations
- Saudi ArabiaIndiaAustralia
In The Last Decade
Abdulrahim Refdan Hakami
30 papers receiving 351 citations
Peers
Comparison fields: 5 of 92
- Complementary and alternative medicine 35
- Toxicology 14
- Computational Theory and Mathematics 67
- Infectious Diseases 59
- Pharmacology 27
Countries citing papers authored by Abdulrahim Refdan Hakami
This map shows the geographic impact of Abdulrahim Refdan Hakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdulrahim Refdan Hakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdulrahim Refdan Hakami more than expected).
Fields of papers citing papers by Abdulrahim Refdan Hakami
This network shows the impact of papers produced by Abdulrahim Refdan Hakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdulrahim Refdan Hakami. The network helps show where Abdulrahim Refdan Hakami may publish in the future.
Co-authors
The 25 scholars most cited alongside Abdulrahim Refdan Hakami, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 59 | |
| 2 | 2022 | 49 | |
| 3 | 2021 | 30 | |
| 4 | 2020 | 28 | |
| 5 | 2021 | 26 | |
| 6 | 2021 | 15 | |
| 7 | 2021 | 13 | |
| 8 | 2020 | 13 | |
| 9 | 2021 | 12 | |
| 10 | 2013 | 12 | |
| 11 | 2023 | 11 | |
| 12 | 2023 | 11 | |
| 13 | 2022 | 9 | |
| 14 | 2021 | 9 | |
| 15 | 2019 | 9 | |
| 16 | 2023 | 8 | |
| 17 | 2021 | 8 | |
| 18 | 2015 | 8 | |
| 19 | 2021 | 6 | |
| 20 | 2020 | 3 |
About Abdulrahim Refdan Hakami
Abdulrahim Refdan Hakami is a scholar working on Infectious Diseases, Computational Theory and Mathematics, Cancer Research, Hematology and Critical Care and Intensive Care Medicine, having authored 33 papers that have together received 356 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (5 papers), Diabetes and associated disorders (3 papers), Blood groups and transfusion (3 papers), MicroRNA in disease regulation (2 papers), COVID-19 Clinical Research Studies (2 papers), Transgenic Plants and Applications (2 papers), CRISPR and Genetic Engineering (2 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Complementary and alternative medicine (35 citations), Toxicology (14 citations), Computational Theory and Mathematics (67 citations), Infectious Diseases (59 citations) and Pharmacology (27 citations). Abdulrahim Refdan Hakami has collaborated with scholars based in Saudi Arabia, India and Australia. Frequent co-authors include Ali G. Alkhathami, Khaled S. Allemailem, Mohammad Y. Alshahrani, Irfan S. Ahmad, Mahmoud Moustafa, Mahmoud A. A. Ibrahim, Mohamed A. M. Atia, Alaa H. M. Abdelrahman, Mohammed Y. Ghazwani and Abdulrahman Abdulaziz Almehizia. Their work appears in journals such as Molecules, Marine Drugs, Journal of Oncology, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics and Future Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.